Patent · US Active

Antibodies against CDCP1 for the treatment of cancer

US8883159B2 · kind B2 · utility

3Cited by

2References

10Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Birgit Bossenmaier · Hanerau-Hademarschen, DE
Georg Fertig · Penzberg, DE
Hans-Willi Krell · Penzberg, DE
Reiner Lammers · Lörrach, DE
Alexander Lifke · Penzberg, DE
Gerhard Niederfellner · Oberhausen, DE

Key dates

Filing date	Aug 26, 2010
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Dec 8, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.